


## American Heart Association Policy Statement on Drug Formularies

Underlined terms are defined on page 4 of the document.

- 1. The AHA supports a <u>formulary system</u> that:
  - Assures access to the range of pharmaceuticals that patients with cardiovascular disease may need
  - !s under the supervision of "ualified physicians#pharmacists#and other appropriate health professionals
  - Provides protocols for the procurement#storage#distri\$ution#and safe use of




- 5. ' hen necessary#the AHA supports <u>therapeutic interchange</u>#including the practice of <u>generic su\$stitution</u>#in designated circumstances. !n the case of <u>narrow</u> <u>therapeutic inde6 drugs</u>#the AHA does not support generic%to%generic interchange.
- 7. 'hen therapeutic interchange does occur#the patient should \$e notified ver\$ally# in writing#or electronically#\$efore or at the point of distri\$ution. In the a\$sence of a colla\$orative drug therapy management -8DT\*. protocol#the provider should \$e notified ver\$ally#in writing#or electronically#\$efore or at the point of distri\$ution.
- 9. The AHA supports transparency of pharmacy \$enefit information for consumers so that they may ma) e informed decisions regarding medical products. In this way# formulary information#encompassing the pharmaceutical products included#their tier and level of cost sharing#processes for changes or ad(ustments#as well as restriction strategies must \$e made transparent to the consumers in an understanda\$le format \$efore they purchase their plan. Similarly#AHA opposes clauses in contracts \$etween pharmacies and \$enefit managers -P: \* s. that prohi\$it pharmacists from discussing different payment options with patients. These clauses are often referred to as 2gag clauses.3

; .




1>. Decisions a sout particular medications for use sy a patient should se made sy the patient and provider. The AHA supports the prescriser, a sility to override#without undue administrative surden#the susstitution of a restricted#non%formulary#or



## **Definitions**

: iosimilars: 2A eneric 3  $\circ$  iologics that are copies of a therapeutic protein #not



## Ac) nowledgements

The preceding policy statement concerning drug formularies was updated and approved \$y an e6pert panel convened \$y the American Heart Association? American Stro) e Association.

The preceding policy statement was approved \$y the American Heart Association,s Advocacy 8oordinating 8ommittee on / cto\$er &1#&>1; .

<sup>&</sup>lt;sup>i</sup> Available at: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm